Dr. Justin Abbatemarco talks with Lizzy Lawrence about the FDA's shift toward single-trial drug approvals and its implications for neurology, rare diseases, and broader effects on drug approval standards and healthcare access. Read the related article on STAT News. Disclosures can be found at Neurology.org.